| Literature DB >> 32840202 |
Katherine Gass1, Michael Deming2, Roland Bougma3, Franck Drabo3, Edridah Muheki Tukahebwa4, Square Mkwanda5, Reina Teresa Velasquez6, Rosa Elena Mejia7, Pamela Sabina Mbabazi8.
Abstract
Coverage evaluation surveys (CESs) are an important complement to routinely reported drug coverage estimates following mass drug administration for neglected tropical diseases (NTDs). Although the WHO recommends the routine use of CESs, they are rarely implemented. Reasons for this low uptake are multifaceted; one is uncertainty on the best sampling method. We conducted a multicountry study to compare the statistical characteristics, cost, time, and complexity of three commonly used CES sampling methods: the Expanded Program on Immunization's (EPI's) 30 × 7 cluster survey, a stratified design with systematic sampling within strata to enable lot quality assurance sampling (S-LQAS) decision rules, and probability sampling with segmentation (PSS). The three CES methods were used in Burkina Faso, Honduras, Malawi, and Uganda, and results were compared across the country sites. All three CES methods were found to be feasible. The S-LQAS approach took the least amount of time to complete and, consequently, was the least expensive; however, all three methods cost less than $5,000 per district. The PSS design resulted in an unbiased, equal-probability sample of the target populations. By contrast, the EPI approach had inherent bias related to the selection of households. Because of modifications needed to maintain feasibility, the S-LQAS method also resulted in a non-probability sample with less precision than the other two methods. Given the comparable cost and time of the three sampling methods and the statistical advantages of the PSS method, the PSS method was deemed to be the best for CESs in NTD programs.Entities:
Mesh:
Year: 2020 PMID: 32840202 PMCID: PMC7543869 DOI: 10.4269/ajtmh.19-0946
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 3.707
Summary of coverage evaluation survey characteristics by country and district
| Country | District | Sampling methodology | Primary sampling unit | Disease(s) targeted | Drugs assessed | WHO target coverage threshold (%) | Survey population |
|---|---|---|---|---|---|---|---|
| Burkina Faso | Batie | PSS | Enumeration areas | LF | Albendazole and ivermectin | 65 | Everybody (all ages) |
| Dano | S-LQAS | NA | |||||
| Diebougou | EPI | Enumeration areas | |||||
| Honduras | Gracias | EPI | Village | Soil-transmitted helminthiasis | Albendazole | 75 | Children aged 24–59 months |
| Lepaera | S-LQAS | NA | |||||
| San Juan | PSS | Village | |||||
| Malawi | Balaka | S-LQAS | NA | LF | Albendazole and ivermectin | 65 | Everybody (all ages) |
| Machinga | EPI | Village | |||||
| Zomba | PSS | Village | |||||
| Uganda | Amuru | EPI, S-LQAS, and PSS | Village | LF, onchocerciasis, schistosomiasis, and trachoma | Albendazole, ivermectin, praziquantel, and azithromycin | 65, 65, 75, and 80 | Everybody (all ages) |
EPI = Expanded Program on Immunization; LF = lymphatic filariasis; NA = not applicable; PSS = probability sampling with segmentation; S-LQAS = stratified survey with lot quality assurance sampling.
WHO target coverage thresholds for lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, respectively.
Statistical parameters used for sample size calculations across the three sampling methods
| Expanded Program on Immunization’s cluster survey | Stratified survey with lot quality assurance sampling within strata | Probability sampling with segmentation | |
|---|---|---|---|
| Expected coverage ( | 50 | 50 | 50 |
| Desired precision (δ) (%) | 5 | 10 | 5 |
| Confidence level ( | 95 | 95 | 95 |
| Anticipated nonresponse ( | 15 | NA | 15 |
| Anticipated design effect | 4 | NA | 4 |
| Target sample size | 1,537 | 95 | 1,537 |
| Stratum | Single stratum consisting of entire target population | Target population divided into five strata (SAs) | Single stratum consisting of entire target population |
| Selection of PSUs | 30 PSUs selected with probability proportional to the estimated size in total population | 19 EAs/villages selected systematically from within each stratum with probability proportional to estimated size in households | 30 PSUs selected with probability proportional to estimated size in segments |
| Selection of secondary sampling units | Random walk, and enrolling nearest-neighbor households until PSU quota for each PSU is reached | One household selected randomly within each selected EA/village | PSUs selected for the survey sample segmented, and then one segment was selected at random. Fixed sampling interval used to systematically select households within selected segments |
| Selection of individuals within selected households | All eligible persons | A single person selected randomly from among all household members | All eligible persons |
EA = enumeration area; NA = not applicable; PSU = primary sampling unit; SA = supervisory area.
Target sample size does not reflect the inflation for nonresponse.
Stratified survey with lot quality assurance sampling information is for the district-level results from the stratified and weighted analyses of the five strata SAs.
Coverage evaluation survey results by country and sampling methodology
| Country | District | Method | Drug(s) | Number who swallowed drug(s) | Surveyed coverage (%) | Two-sided 95% CI | Design effect | Coverage above WHO threshold? | Reported coverage (%) | Validation of reported coverage | Lower 1-sided 95% CI | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burkina | Diebougou | EPI | ALB + IVM | 1,821 | 1,464 | 80 | (78, 83) | 1.68 | Yes | 84 | No | 78 |
| Dano | S-LQAS | ALB + IVM | 95 | 73 | 74 | (64, 85) | 1.49 | Yes | 83 | Yes | 66 | |
| Batie | PSS | ALB + IVM | 1,783 | 1,477 | 83 | (81, 85) | 1.3 | Yes | 81 | Yes | 81 | |
| Honduras | Gracias | EPI | ALB | 473 | 249 | 53 | (45, 60) | 2.28 | No | 89 | No | 46 |
| Lepaera | S-LQAS | ALB | 92 | 42 | 43 | (33, 54) | 1.08 | No | 42 | Yes | 35 | |
| San Juan | PSS | ALB | 444 | 258 | 58 | (52, 64) | 1.41 | No | 76 | No | 53 | |
| Malawi | Machinga | EPI | ALB + IVM | 1,851 | 1,359 | 73 | (70, 77) | 2.48 | Yes | 89 | No | 70 |
| Balaka | S-LQAS | ALB + IVM | 94 | 79 | 86 | (79, 93) | 0.97 | Yes | 87 | Yes | 80 | |
| Zomba | PSS | ALB + IVM | 1,581 | 1,212 | 77 | (73, 80) | 2.14 | Yes | 83 | No | 74 | |
| Uganda | Amuru | EPI | ALB | 1,637 | 648 | 40 | (27, 52) | 22.49 | No | 79 | No | 29 |
| IVM | 1,641 | 806 | 49 | (39, 60) | 16.23 | No | 78 | No | 41 | |||
| PZQ | 1,606 | 339 | 21 | (13, 30) | 15.56 | No | 75 | No | 6 | |||
| ZITH | 1,633 | 304 | 19 | (10, 27) | 18.71 | No | 72 | No | 11 | |||
| S-LQAS | ALB | 85 | 38 | 44 | (33, 56) | 1.18 | No | 79 | No | 35 | ||
| IVM | 84 | 40 | 4 | (35, 59) | 1.13 | No | 78 | No | 37 | |||
| PZQ | 82 | 14 | 13 | (7, 20) | 0.8 | No | 75 | No | 8 | |||
| ZITH | 82 | 18 | 21 | (11, 31) | 1.18 | No | 72 | No | 13 | |||
| PSS | ALB | 1,205 | 568 | 47 | (36, 58) | 12.36 | No | 79 | No | 38 | ||
| IVM | 1,219 | 635 | 52 | (43, 61) | 9.04 | No | 78 | No | 44 | |||
| PZQ | 1,198 | 316 | 26 | (15, 38) | 18.58 | No | 75 | No | 17 | |||
| ZITH | 1,201 | 269 | 22 | (10, 35) | 22.68 | No | 72 | No | 12 |
ALB = albendazole; EPI = Expanded Program on Immunization; IVM = ivermectin; PSS = probability sampling with segmentation; PZQ = praziquantel; S-LQAS = stratified survey with lot quality assurance sampling; ZITH = azithromycin.
Participants who responded “not sure” to the question of whether they swallowed the drug (n = 1,018) were removed from the analysis (both numerator and denominator); this accounted for 4.5% of total respondents.
Time and cost calculations for the three coverage sampling methods
| Expanded Program on Immunization’s cluster survey | Stratified survey with lot quality assurance sampling within strata | Probability sampling with segmentation | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Country | Days required for one team to complete the survey | Mean time to complete sampling in each PSU (minutes) | Cost (training + implementation) ($) | Days required for one team to complete the survey | Mean time to complete sampling in each PSU (minutes) | Cost (training + implementation) ($) | Days required for one team to complete the survey | Mean time to complete sampling in each PSU (minutes) | Cost (training + implementation) ($) |
| Burkina Faso | 18 | 276 | 4,385 | 19 | 59 | 4,816 | 17 | 277 | 4,525 |
| Honduras | 22 | 128 | 1,867 | 9 | 19 | 1,167 | 18 | 164 | 1,520 |
| Malawi | 14 | – | 4,113 | 10 | – | 3,247 | 16 | – | 4,546 |
| Uganda | 23 | 180 | 4,040 | 21 | 29 | 3,835 | 26 | 231 | 4,535 |
| Average | 19 | 195 | 3,601 | 15 | 36 | 3,266 | 19 | 224 | 3,782 |
PSUs = primary sampling units.
Does not include training costs (e.g., facility rental, refreshments, transport of attendees to training site, and photocopies).
Data not available.
Figure 1.Survey team members’ responses to the qualitative questionnaire assessing the feasibility of each survey method; responses are summarized across all four countries. This figure appears in color at